CURRICULUM VITAE Page 1 of 12 Statement of Education and Qualifications Name (First, Middle, Last) ANTONIO CASADO HERRAEZ Academic Qualification(s) (e.g. MD, MBBS, Medical License Number, etc) MD, PhD Current place of work. Address (Name of Institution, Street, City, Postal Code, State or Province (if applicable), Country) Department of Medical Oncology - HOSPITAL UNIVERSITARIO (CLINICO) SAN CARLOS / San Carlos University Teaching Hospital C/PROF, MARTIN LAGOS S/N, 28040 MADRID, SPAIN E-mails: antoniocasado@telefonica.net and acasado.hcsc@salud.madrid.org Telephone Number (Country Code, Area Code, Number) 0034 609 753 403 /0034 91 3303000, ext. 7551 and 7549 FAX Number (Country Code, Area Code, Number) 003434915436623 Education and Training (List all Colleges, Universities and Medical Schools attended incl. postdoctoral/fellowship training, including board certification/medical license) Name and Location of Institution (City, State or Degree and Year Awarded Area of Study Province and Country) UNIVERSIDAD AUTONOMA DE MADRID, MADRID, SPAIN (*) 1983, MD MEDICINE AND SURGERY UNIVERSIDAD COMPLUTENSE DE MADRID, SPAIN (***) TRAINING IN MEDICAL ONCOLOGY: Hospital Universitario San Carlos, Madrid (**) July 2001-February 2008, PhD MEDICAL ONCOLOGY/NTER NAL MEDICINE 1985-1988 Speciality in Medical Oncology Version 01 May 2011
CURRICULUM VITAE Page 2 of 12 (*) 1977-1983: Graduate in Surgery and Medicine from the Universidad Autónoma de Madrid. Pass with distinction. 1983: Graduated from the Universidad Autónoma de Madrid. Qualification obtained: Firstclass. (**) 1985 1989: Spanish National Medical Training Scheme (MIR): Internship in Medical Oncology through the national MIR system in the speciality of Medical Oncology at the Medical Oncology Service of the San Carlos University Teaching Hospital, Madrid 1984 1987: PhD. Four courses studied. (***) 2001: Advanced Studies Diploma (ASD). "Randomized study of two dosage levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in advanced cancer. Mark obtained: Excellent. Doctoral thesis on anorexia and cancer: Cum Laude (February 2008). 2005 onwards: Associate Professor Professional Experience (#) Position/Title Current STAFF MEDICAL ONCOLOGY DEPARTMENT / Senior Consultant ASSOCIATE PROFESSOR Name and Location of Institution (City, State or Province and Country) HOSPITAL UNIVERSITARIO CLINICO SAN CARLOS, MADRID, SPAIN UNIVERSIDAD COMPLUTENSE DE MADRID, SPAIN Dates (Start/Stop Dates as applicable) 1989-CURRENT 2005-CURRENT (#) Main areas of professional interest: gynaecological tumours, sarcomas of soft tissue and bones, breast cancer, tumours of unknown origin and supportive treatment. Services rendered include house officer at the Medical Oncology Service of the San Carlos University Teaching Hospital in Madrid from April 1st 1989, to the present. Member of the EORTC Gynaecological Cancer Group (GCG) since 1995-1996. Secretary to the EORTC GCG from March 2003 to March 2009. Chairman to the EORTC GCG since March 2009. Member of the Soft tissue and bone sarcoma group of the EORTC since November 2002. National cooperative groups: GEICAM Group (Spanish Group for breast cancer research), since 1994. GEICO Group (Spanish Group for ovarian cancer and gynaecological tumour
CURRICULUM VITAE Page 3 of 12 research), since 1996. GEIS Group (Spanish Group for research into soft tissue and bone sarcoma), since 1996 (#) Other Medical Interest Member (associate) of the Spanish Society for Medical Oncology (SEOM) since 1987 and full member since 1989, to the present Member of the European Society for Medical Oncology (ESMO) since September 1989. Member of the American Society of Clinical Oncology (ASCO) from July 2000 to December 2007. Member of the European Society of Gynaecological Oncology (ESGO) since 2006.
CURRICULUM VITAE Page 4 of 12 Research Participation in several clinical and basic research projects on gynaecological cancers, breast cancer, soft tissue and bone sarcoma, thyroid cancer and tumours of unknown origin Participation in national and international phase I, II and III studies. Previous participation in clinical trials (Required Information for Investigators in the European Union) Indication of Trial Clinical Phase of Trial (I-IV) Role in Trial (e.g. Investigator, Sub-Investigator) Year in which trial was conducted SEVERAL TRIALS: GYNAECOLOGICAL I,II, III PI / SUB-INV 1988-CURRENT CANCER, BREAST CANCER, SOFT TISSUE AND BONE SARCOMA, THYROID CANCER Training on ICH/GCP: YES X If yes, specify below NO During Several trials Other documents evidencing experience or expertise attached: YES If yes, specify below NO X Publications in English Language Signature (if required) Date
CURRICULUM VITAE Page 5 of 12 Personal data Date of birth: January 18, 1959 Marital status: Married to Esther Martin and enjoying Nadia and Paula. ID card no: 1.913.391 Home address (Street, City, Postal Code, State or Province -if applicable-, Country) C/ Las Naves nº 18, 4º - A. MADRID 28005 Spain Telephone Number Mobile phone number +34 609 753 403 FAX Number 34-91-474 23 61 (Private) Appendix. Publications: more than 80 papers co-authored and published in English language in international Journals. 1. Martín M, Díaz-Rubio E, Casado A, López Vega JM. Phase II study of carboplatin in breast cancer: Preliminary results. Seminars in Oncology 1 (Suppl 2): 23-27, 1991. 2. Palmeiro R, Díaz-Rubio E, Martín M, González JL, Casado A, García del Muro A, López Vega JM, Lozano Setien E. Time trends of some risk factors of breast cancer. J Cancer Res Clin Oncol 1990; 116 (Suppl., Part 1): 349. 3. Martín M, Díaz-Rubio E, Casado A, López Vega JM. Phase II Study of Carboplatin in Breast cancer: Preliminary results. J Cancer Res Clin Oncol 1990; 116 (Suppl., Part I): 1097. 4. Martín M, Díaz-Rubio E, González Larriba JL, Casado A, Sastre J, López-Vega JM, Almenarez J, Domínguez S. Phase II study of Ifosfamide in head and neck cancer. Cancer Chemotherapy and Pharmacology (1993): 31: 340-342. 5. Martín M, Díaz-Rubío E, Casado A, López Vega JM, Sastre J, Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controled trial. American Journal of Clinical Oncology 15 (3): 1992, 348-351. 6. Miguel Martín, E. Díaz-Rubio, Antonio Casado, Severina Domínguez, Javier Sastre. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. A study of 107 patients treated with 6 courses of FAC (5-FU, Adriamycin, cyclophosphamide) chemotherapy. The European Journal of Cancer 28: 430-432; 1992. 7. Miguel Martín, Eduardo Díaz-Rubio, Antonio Casado, Pedro Santabárbara, José Manuel López Vega, Encarna Adrover, Luigi Lenaz. Carboplatin: an active drug in metastatic breast cancer. Journal of Clinical Oncology 10: 433-437, 1992.
CURRICULUM VITAE Page 6 of 12 8. García-Conde J, Lluch A, Casado A, et al. Phase II trial with Navelbine in advanced breast cancer previously untreated. Breast Cancer Res Treat 23: 142, 1992 (Abstr 52). 9. Martín M, Casado A, Lluch A*, Adrover E, Díaz-Rubio E, and García-Conde *. Preliminary results of a phase II trial of chronic oral etoposide in breast cancer. Cancer Treatment Review (1993) 19 (Supplement C), 47-52. 10. Martín M, Díaz-Rubio E, Casado A, Valverde JJ, García Urra D, López Martín JA. Prednimustine-induced myoclonus. A report of three cases. Acta Oncol 33: 81-82, 1994. 11. Sastre J, Martín M, Díaz-Rubio E, González Larriba JL, Casado A, Domínguez S, and López-Vega JM. Aztreonam in association with piperacillin as an empirical antibiotic treatment in febrile granulocytopenic patients with solid tumors. Oncolgy Reports 1: 233-236, 1994. 12. García-Conde J (1), Lluch A (1), Martín M (2), Casado A (2), Gervasio H (3), De Oliveira C (3), De Pablo JL (4), Gorostiaga J (4), Girón GC (5), Cervantes A (1), Martínez A (6), Pezous N (6), Delgado FM (6) and Díaz- Rubio E (2). Phase II trial of weekly i.v. vinorelbine in first line advanced breast cancer chemotherapy. (1) H. Clínico Universitario de Valencia. (2) H. Clínico Universitario de Madrid. (3) Hospitais de Universidade, Instituto de Oncología, Coimbra, Portugal. (4) H. Txagorritsu, Vitoria, Spain. (5) H. General Yagüe, Burgos, Spain. (6) Pierre Fabre Research Centre. Annals of Oncology 5: 854-857, 1994. 13. Martín M (1), Lluch A (2), Casado A (1), Santabárbara P (3), Adrover E (1), Valverde JJ (1), López-Martín JA (1), Rodríguez Lescure A (1) García-Conde J (2) y Díaz-Rubio E (1). Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. University Hospitals of Madrid (1) and Valencia (2), and Bristol- Myers Squibb (3), Spain. Journal of Clinical Oncology Vol 12, No 5, 1994, pp 986-991. 14. Díaz-Rubio E, MD, PhD, Martín M, MD, PhD, López-Vega JM, MD, Casado A, MD, Benavides A, MD*. Medical Oncology Department, San Carlos University Hospital, Madrid. Laboratorios Knoll, SA, Madrid. Phase I study with Mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. Investigational New Drugs 12: 277-281, 1994. 15. Bohn U*, González JL, Martín M, Casado A, Díaz-Rubio E & Aragoncillo P. Meningeal and brain metastases in primary malignant pericardial mesothelioma. Letters to the editor: Meningeal and brain metastases in primary malignant pericardial mesothelioma. Annals of Oncology, Vol 5, Nº7, 1994, pp 660-661. 16. Sastre J, Díaz-Rubio E, Alonso MC, González ML, Martín M, González Larriba JL and Casado A. Neutropenic enteritis: A two case report and literatura review. Oncology reports 1: 1211-1215, 1994. 17. Barnadas A, Mendiola C, Casado A, et al. Combination of oral idarubicin and prednimustine in advanced breast cancer. European Journal of Cancer 33 (2): 312-315, 1997. 18. Martín M*, Aranda E, Díaz-Rubio E*, Casado A*, Rubio Mª J, Valverde JJ*, López Martín JA*, Lescure AR*, Barneto IC and González R. Emetic control in breast cancer patients receiving i.v. CMF: Results of two consecutive studies using a new method of assessment * Servicio de Oncología Médica, San Carlos University Teaching Hospital, Madrid, and Servicio de Oncología Médica, Hospital Reina Sofía, Córdoba, Spain. Oncology Reports 3: 115-121, 1996. 19. Fernández-Marcos A, Martín M, Sánchez JJ, Rodríguez-Lescure A, Casado A, López-Martín JA, Díaz-Rubio E. Acute and anticipatory emesis in breast cancer patients Support Care Cancer, 4: 370-377, 1996. 20. Antonio Casado (1), Rafael Rosell (2), Ramón García-Gómez (3), Eduardo Díaz-Rubio (1), Gumersindo Pérez-Manga (3), Ana Benavides (4) and Miguel Martín (4). (1) University Hospital, Madrid. (2) University Hospital, Badalona. (3) Community Hospital, Madrid. (4) Knoll Laboratories, S.A. Madrid. Spain. Phase II study of Mitonafide in non-small cell lung cancer (NSCLC). Investigational New Drugs 14: 415-417, 1996. 21. Martín M, Casado A, López-Martín JA, Rodríguez-Lescure, Nieto Y, Ayala F, Díaz-Rubio E. UFT/Methotrexate/Leucovorin for breast cancer patients in progression after HDCT/PBPC support. Oncology, 11 (9) (Supplement 10). 1997; pp 82-85. 22. Cervantes, A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda
CURRICULUM VITAE Page 7 of 12 A, Benito D. Dose escalated Paclitaxel in 1-hour infusion with a fixed dose of Cisplatin in previously untreated advanced ovarian cancer: A phase II trial of the Spanish Group for Ovarian Cancer. Seminars in Oncology, vol 24, Nº 5, Suppl 15 (October), 1997: pp S15-S15-S43. 23. Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, De Andrés, L, Escudero P, Poveda A, Casado A. Phase II trial of first line high dose ifosfamide in advanced soft tissue sarcomas of the adult. A study of the Grupo Español de Investigación en Sarcomas. Ann Oncol 1998; 9: 871-876. 24. Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro J, Escudero P, Casado A. Activity of doxorubicin after high dose ifosfamide in adult patients with advanced soft tissue sarcoma. A study of the Grupo Español de Investigación en Sarcomas. Annals of Oncology 1998; 9: 783-785. 25. García-Patiño, E, Gomendio B, Silva JM, García JM, Provencio M, Pérez-Carrión R, Lianes P, Casado A, España P, Bonilla F. Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. International journal of Oncology 1998; 13:275-279. 26. Martín M, Casado A, Llorente L, García-Carbonero I, García Sáenz JA and Díaz-Rubio E. Long-term diseasefree survival in disseminated breast cancer patients treated with conventional and high-dose chemotherapy: Predictive factors and therapeutic implications. In: Veronesi U, Aapro MS and Rosti G (eds). Dose and timing: The pillars of successful chemotherapy. ESO Scientific Updates, vol 3. Elsevier Science 1998; pp. 33-52. 27. Nieto Y, Martín M, Alonso JL, Casado A, Ayala F, López-Martín JA, Rodriguez-Lescure A, Díaz-Rubio E. Weekly continuos infusion of 5-Fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistence to doxorubicin. Breast Cancer Research and Treatment 1998; 50:167-174. 28. Martín M, Alfonso R, Casado A, Oruezabal M, García Sáenz JA, García Carbonero I, Díaz-Rubio E. MUL CT (methotrexate, UFT, leucovorin) for breast cancer patients (BCP) in progression after high-dose chemotherapy and PBPC support (HDCT-PBPC). Breast Cancer Research and Treatment 1998; 50 (3): 145. 29. Jara C, Martín Jimenez M, Alonso C, García-Carbonero I, Fernández A, Casado A, Gómez-Aldaraví L, Pelegrí A, López-Vega JM, Batista N, Cuevas JM, González-Mancha MR, Menendez MD, Alba E, Anton A, Cassinello J, Balil A. Grupo GEICAM. Spain. Phase II trial of vinorelbine (VNB) in 96-hours continuos infusion (CI) in metastatic breast cancer refractory to anthracyclines. Breast Cancer Research and Treatment 1998; 50 (3): 229. 30. Martín M, Casado A, Pérez-Segura P, García Carbonero I, Díaz-Rubio E, Lluch A, García Conde J. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines. Oncology 1998; 12 (Suppl.1) (1): 28-30. 31. M. Martín, A. Casado, A. Benavides, JL Alonso, I. García Carbonero, J. Sastre, E. Moreno, E. Díaz-Rubio. Phase I study of Elinafide in solid tumors. Annals of Oncology 1998; (9)(Suppl 2): 63. 32. Nieto Y, Alonso JA, Ayala F, Ortega L, Casado A, Martín M, Díaz-Rubio E. End stage acute hepatic failure as clinical presentation of liver metastases from breast cancer. Tumori 85(5): 616-617, 1998. 33. J. Cuesta, L. Llorente, J. Díaz-Mediavilla, A. Álvarez, E. Del Potro, R. Martínez, A. González, A. Villegas, A. Casado, M. Martín y C. Fernández. Characteristics of the mobilization and transplant of CPSP mobilized with G-CSF in different onco-haematological diseases. Haematologica, Journal of Haematology 1998; 83 (supl.2): 57. 34. I. García-Carbonero, A. Casado, M. Martín, et al. DICEP high dose (HD-DICEP) chemotherapy (CT) with or without peripheral blood stem cell support as consolidation treatment of patients (pts) with advanced epithelial ovarian cancer (AOC). The European Journal of Cancer 1999; 35 (suppl.4): S237. 35. M. Martín, I. García-Carbonero, A. Casado, M. Oruezabal, JA Macias, J. A. García Sáenz, I. Manrique, E. Díaz- Rubio. Weekly taxol plus navelbine in metastatic breast cancer patients (MBCP) with prior doxorubicin treatment. Breast Cancer Research and Treatment, vol 57 (1) 1999; p 90. 36. M. Martín, A. Lluch, A. Casado, I. García-Carbonero, L. de Paz, C. Esteban, A. Insa, R. Alfonso, J. García-Conde, E. Díaz-Rubio. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior
CURRICULUM VITAE Page 8 of 12 anthracycline exposure. Annals of Oncology 2000; 11: 85-89. 37. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, H, Cortés-Funes, Lloveras B. Circulating HER-2 extracellular domain and ressitance to chemotherapy in advanced breast cancer. Clinical Cancer Research 2000; 6:2356-2362. 38. Lluch A, Ojeda B, Barnadas A, Colomer R, Massuti B, Casado A, Angeles C, Maroto P. Paclitaxel and doxorubicin combination in advanced breast cancer: importance of prior adjuvant anthracycline therapy. Cancer 2000; 89:2169-2175. 39. Martín M, Casado A, Macias JA, García-Carbonero I, García-Sáenz JA, Oruezabal M, Manrique I, Díaz-Rubio E. Methotrexate, Uracil and Tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemoltherapy with peripheral blood progenitor cell transplant. A phase II study. Am J Clin Oncol 2000; 23(6): 617-621. 40. J.J Valverde, M. Martín, JA Gª Asenjo, A. Casado, JA Vidart, V. Furio, A. Pelayo, MA Herraíz, E. Díaz-Rubio. Prognostic value of DNA Quantification in early epithelial ovarian carcinoma. Obstetrics & Gynecology 2001; 97:409-416. 41. B. Ojeda, LM de Sande, A. Casado, P Merino, and MA Casado. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. British Journal of Cancer 2003; 89: 1002-1007. 42. M.Martín, A. Villar, A. Solé-Calvo, R. González, B. Massuti, J. Lizón, C. Camps, A. Carrato, A. Casado, MT Candel, J. Albanell, J. Aranda, B. Munarriz, J. Campbell & E. Díaz-Rubio. On behalf of the GEICAM Group (Spanish Breast Cancer Research Group), Spain. FAC (flourouacil, doxorubicin, cyclophosphamide) versus CMF (cyclophosphamide, methotrexate, florouracil) as adjuvant chemotherapy for operable breast cancer. Annals of Oncology 2003; 14:833-842. 43. M. Martin, M.Spielman, M. Namer, A.du Bois, C. Unger, D. Dodwell, P. Vodvarka, M. Lind, H. Calvert, A. Casado, L. Zeleck, A. Lluch, E. Carrasco, L. Kayitalire & C. Zielinski. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Annals of Oncology 2003; 14:1246-1252. 44. Carlos Jara-Sánchez, Miguel Martín, Jose A. García-Sáenz, Agustí Barnadas, Antonio Fernandez-Aramburo, José M. Lopez-Vega, Amadeu Pelegrí, Emilio Alba, Antonio Casado. On behalf of the GEICAM group. Vinorelbine as 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative Study by the GEICAM Group. Clinical Breast Cancer 2003; 3 (6): 399-404. 45. Miguel Martin, Jésus García Donas, Antonio Casado, Isabel de la Gándara, Pedro Pérez Segura, José Angel García Sáenz, Gabriel Ibañez, Belen Loboff, Gemma García-Ledo, Fernando Moreno, Enrique grande, Eduardo Díaz-Rubio. Phase II study of pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with Previous Anthracycline Exposure. Clinical Breast Cancer 2004; 5 (5): 353-357. 46. Joan Maurel, Joaquin Fra, Antonio López-Pousa, Xavier García del Muro, Carmen Balaña, Antonio Casado, Javier Martín, javier Martinez-Trufero, Ramón de las Peñas, José María Buesa. Sedquential Dose-Dense Doxorubicin and ifosfamide for advanced soft tissue sarcomas. A phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004; 100:1498-506. 47. Joan Maurel, José Buesa, Antonio López-Pousa, Xavier García del Muro, María Jesús Quintana, Javier Martín, Antonio Casado, Javier Martínez-Trufero, Ramón de las Peñas and Carmen Balaña. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias-a study of the Spanish Group for Research on Sarcomas (GEIS). J Surg Oncol 2004; 88:44-49. 48. Emilio Alba, Miguel Martin, manuel Ramos, Encarna Adrover, Ana balilo, Carlos Jara, Agustí Barnadas, Antonio Fernández-Aramburu, Pedro Sanchez-Rovira, Margarita Amenedo y Antonio Casado. Multicenter randomized trial comparing sequential with concomitant administration of Doxorubicin and Docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903). J Clin Oncol 2004; 22: 2587-2593.
CURRICULUM VITAE Page 9 of 12 49. Clara Sanz, Fernando Moreno, Alvaro Armas, Antonio Casado and MC Castillo. Groin angiosarcoma following radiotherapy for vulvar cancer. Gynecologic Oncology 2005; 97: 677-680. 50. AJ González-Martín, E.Calvo, I. Bover, MJ Rubio, A. Arcusa, A. Casado, B. Ojeda, C.Balaña, E. Martinez, A. Herrero, B. Pardo, E. Adrover, J. Rifá, MJ Godes, A. Moyano, A.Cervantes. Randomized phase II trial of carboplatin vedrsus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de investigación en Cáncer de Ovario) Study. Annals of Oncology 2005; 16:749-755. 51. Nicholas S Reed, Antonio Casado. European Collaborative Approach to Gynaecological Cancer Management. Business Briefing: European Pharmacotherapy 2005; 82-84. 52. Xavier García del Muro, Antonio López Pousa, Javier Martin, José María Buesa, Javier Martínez Trufero, Antonio Casado, Andrés Poveda, Josefina Cruz, Isabel Bover, Joan Maurel. Phase II trial of temozolamide as a 6 week continuous ofral schedule in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) Study. Cancer 2005; 104: 1706-1712. 53. José A. García Sáenz, Miguel Martín, Javier Puente, Sara López-Torruella, Antonio Casado, Fernando Moreno, Enrique Grande, Eduardo Díaz-Rubio. Trastuzumab associated with successive cytotoxic therapies beyond disease progresión in metastatic breast cancer. Clin Breast Cancer 2005; 6(4): 325-329. 54. Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, Gracía del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martinez J, De Juan A, Laínez N, Ferrán L, Alija V, Escudero P, Casado A, García P, Blanco R, and Buesa JM. Deletions affecting codons 557-558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Researh (GEIS). Journal of Clinical Oncology 2005; 23: 6190-6198. 55. Poveda A, A. López-Pousa, J. Martín, J. García del Muro, R. Bernabé, A.Casado, C.Balaña, O. San Martín, M.D. Menéndez, P. Escudero, J. Cruz, Elena Belyakova, D. Menéndez & J.M. Buesa. Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx/Doxil) and quality of life evaluation (EORTC QLQ-C-30) in adult patients with advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 2005; 9 (3-4):127-132. 56. G. Stuart, E. Avall-Lundqvist, A. du Bois, M. Bookman, D. Bowtell, M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlander, K. Fujiwara, S. Grenman, JP Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchener, G. Kristensen, R. Mannel, W. Meier, B. Miller, A. Oza, R. Ozols, M. Parmar, J. Pfisterer, A. Poveda, D. Provencher, E. Pujade-Lauraine, M. Quinn, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, E. Trimble, T. Thigpen, P. Vasey, I. Vergote, R. Verheijen, J. Vermorken, U. Wagner. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Annals of Oncology 2005; 16 (Suppl 8):viii36-viii38. 57. A. Du Bois, M. Quinn, T. Thigpen, J.B. Vermorken, E. Avall-Lundqvist, M. Bookman, D. Bowtell, M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlander, K. Fujiwara, S. Grenman, JP Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchner, G. Kristensen, R. Mannel, W. Meier, B. Miller, JP Neijt, A. Oza, R. Ozols, M. Parmar, S. Pecorelli, J. Pfisterer, A. Poveda, D. Provencher, E. Pujade-Lauraine, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, G. Stuart, E. Trimble, P. Vasey, I. Vergote, R. Verheijen, U. Wagner. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology 2005; 16 (Suppl. 8):viii7-viii12. 58. M. Quinn, J. Pfisterer, E. Avall-Lundqvist, M. Bookman, D. Bowtell, A. Casado, A. Cervantes, S. Grenman, P. Harper, A. Oza, S. Pecorelli, E. Pujade-Lauraine, E. Trimble, P. Vasey and U. Wagner. Integration of new or experimental treatment options and new approaches to clinical trials. Annals of Oncology 2005; 16 (Suppl. 8): viii30-viii35.
CURRICULUM VITAE Page 10 of 12 59. A. López-Pousa, R. Losa, J. Martín, J. Maurel, J. Fra, M. Sierra, A. Casado, J. García del Muro, A. Poveda C. Balaña, J. Martinez-Trufero, E. Esteban and JM Buesa. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas. A GEIS study. British Journal of Cancer 2006; 19; 94(12):1797-802 (online publication 23 May 2006;doi:10.1038/sj.bjc.6603187). 60. A. López-Pousa, J. Martín, J. Montalar, R. de las Peñas, J. García del Muro, J. Cruz, J. laurel, P. Escudero, A. Casado, J.M. Buesa, and the Spanish Group for Research on Sarcomas (GEIS). Phase II trial of Doxorubicin plus escalated high-dose ifosfamide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 2006 (Sept 19): 1-8 (article ID 26986). 61. Javier Puente Vázquez, Sara López-Tarruella Cobo, Fernando Moreno Antón, Antonio Casado Herráez, José Antonio Vidart, Pluvio Coronado, Eduardo Díaz-Rubio. Brain metastasis and carcinomatous meningitis from vulvar squamous cell carcinoma: case report. European Journal of Gynaecological Oncolgy 2007 (2): 152-154. 62. Casado, A, Reed, N. Treatment strategies for ovarian cancer. Touch Briefing. European Oncological Disease 2006 (in press). 63. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; (109): 645-649. 64. Miguel Martín, Amparo Ruiz, Monserrat Muñoz, Ana Balil, Jesús García Mata, Lourdes Calvo, Eva Carrasco, Esther Malillo, Antonio Casado, José Angel García-Sanz, M José Escudero, vicente Guillem, Carlos Jara, Nuria Ribelles, Fernando Salas, Celia Soto, Flavia Morales-Vasquez, César A. Rodríguez, Encarna Adrover, José Ramón Mel. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.lancet Oncol 2007; 8:219-225. 65. José A García-Sáenz, Miguel Martín, Antonio Calles, Coralia Bueno, Laura Rodriguez, Jana Bobokova, Ana Custodio, Antonio Casado and Eduardo Díaz-Rubio. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline and taxane-refractory breast cancer. J Chemother. 2008 Oct;20 (5): 632-9 66. Ojeda, G B, González Martín, A, Bover Barcelo I, Fabregat i Mayol, I, Mellado B, Rubio Pérez, MJ, Alonso Carrión L, Casado Herráez, A, Calvo García, E, Churruca Galaz, C, Arcusa Lanza, A, Herrero Ibañez, A, Adrover Cebrián, E, Poveda Velasco, A. A phase II trial of fixed-dosed rate gemcitabine in platinumresistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial. Am J Clin Oncol 2008; Oct; 31 (5): 481-487. 67. Martín-Broto J, Gutierrez A, García del Muro X, López-Guerrero JA, Martínez-Trufero J, de Sande LM, Laínez N, Maurel J, de Juan A, Losa F, Andrés R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gómez- España A, Ramos R, Martínez-Serra J, Llombart Bosch A, Poveda A. Prognostic time dependence of deletions affecting codón 557 and/ or 558 of KIT gene for relapse-free survival (RFS) in localizaed GIST: A Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010; Jul 21 (7):1552-7. Epub 2010 Mar 15. 68. Miguel Martín, José Angel García Sáenz, Maria Luisa Maestro de las Casas, Marta Vidaurreta, Javier Puente, Silvia Veganzones, Laura Rodriguez Lajusticia, Virginia de la Orden, Belen Oliva, Julio césar de la Torre, Sara López Tarruella, Antonio Casado, Javier Sastre and Eduardo Díaz-Rubio. Circulating tumour cells in metastatic breast cáncer: timing of blood extraction for analysis. Anticancer Research 2009; 29:4185-4188. 69. Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wocjtukiewitz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C, Yondelis Ovarian Cancer Group (*). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to
CURRICULUM VITAE Page 11 of 12 patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20 (11): 1794-1802. (*) Author collaborator: A Casado. 70. Joan Maurel, Ana Sofia Martins, Andrés Poveda, Ricardo Cubedo, Antonio Casado, Javier Martínez-Trufero, Juan Ramóin Ayuso, Antonio López-Pousa, Xabier García -Albeniz, Xavier García del Muro and Enrique de Alava. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumours refractory to high-dose imatininb: A phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010 Apr 29 (DOI: 10.1002/cncr.25111). 71. Ignace Vergote, Eric Pujade-Lauraine, Sandro Pignata, Gunnar Kristensen, Jonathan Ledermann, Antonio Casado, Jalid Sehouli, Maansor Mirza, Roldano Fossati, Christian Marth, Carine Creutzberg, Jose del Campo, Nadeem Siddiqui, Paula Calvert, Aris Bamias, Gokhan Tulunay, Ate van der Zee and Andreas du Bois on behalf of the member trial groups of European Network of Gynaecology Oncological Trial Groups (ENGOT). European Network of Gynaecological Oncological Trial Group s Requirements for Trials between Academic Groups and Pharmaceutical Companies. Int J Gynecol Cancer 2010; 20: 476-478. 72. Alba E, Ruiz-Borrego M, Margelí M, Rodriguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Marquez A, Vicente D, García Sáenz JA, Martín M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cáncer: GEICAM 2001-01 study. Breast Cancer Research Treatment 2010; 122 (1): 169-176. 73. Baptist Trimbos, Petra Timmers, Sergio Pecorelli, Corneel Coens, Koen Ven, Maria van der Burg, Antonio Casado. Surgical staging and treatment of early ovarían cáncer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102: 982-987. 74. Ignace Vergote, Claes G. Tropé, Frederic Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, René HM Verheijen, Maria E.L. van der Burg, Angel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Corneel Coens, Leen Verleye, Gavin CE Stuart, Sergio Pecorelli, and Nick Reed, for the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and the NCIC Clinical Trials Group- A Gynecologic Cancer Intergroup Collaboration. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine 210; 363: 943-953. 75. Ignace Vergote, Corneel Coens, Antonio Casado. Neoadjuvant Chemotherapy or Primary Surgery in Advanced Ovarian Cancer. Authors reply. New England Journal Medicine 2010. Dec 9; 363 (24): 2371-72. 76. M. Martin, P. Sánchez-Rovira, M. Muñoz, J.M. Baena-Cañada, J.R. Mel, M. Margeli, M. Ramos, E. Martínez, J. A. García-Sáenz, A. Casado, A. M. Jaén, X. González-Farré, M.J. Escudero, C. Rodiriguez-Martín & E. Carrasco on behalf of GEICAM. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER-2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Annals of Oncology (advance Access published March 17, 2011). 77. Gordon JS Rustin, Maria EL van der Burg, Clare L Griffin, David Guthrie, Alan Lamont, Gordon C Jayson, Gunnar Kristensen, César Mendiola, Corneel Coens, Wendi Qian, Mahesh KV Parmar, Ann Marie Swart, for the MRC OV05 and EORTC 55955 investigators (*). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05 / EORTC 55955): a randomized trial. Lancet 2010; 376: 1155-1163.(*) Author collaborator: A. Casado Herráez 78. Anton A, Lluch A, Casado A, Provencio M, Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J, Martin M. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anticancer Research 2010; 30 (6): 2256-2261.
CURRICULUM VITAE Page 12 of 12 79. Paz-Ares L, López-Pousa A, Poveda A, Balaña C, Ciruelos E, Bellmunt J, Del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovic A, Cortés-Funes H, Buesa JM. Trabectedin in pretreated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2010; Oct 20 (Epub ahead of print). 80. Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martinez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel JF, F Pons F. Q J Nucl Med Mol Imaging 2010 Dec 9 (Epub ahead of Print). 81. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda D, Ghataje P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel versus carboplatin-paclitaxel. J Natl Cancer Inst 2010; 102 (20): 1547-1556. 82. Martin M, Romero A, Cheang MC, López García-Asenjo JA, García Sáenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Cáldes T, Vidart JA, López-Tarruella S, Díaz-Rubio E, Perou CM. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011 April 5 (Epub ahead of print).